Solaris Vaccines, Inc.
Solaris Vaccines, Inc. was established in 2021 with the mission to develop rapid, safe, and effective vaccines for global health challenges. They utilize the innovative SolaVAX™ platform, which employs riboflavin and UV light to inactivate pathogens, offering a faster and potentially safer alternative to traditional vaccine methods. The company's vision is to address the limitations of current vaccine development and manufacturing processes, providing flexible, low-cost, and globally distributable vaccines, including for emergent threats like COVID-19 and Dengue.
Industries
Nr. of Employees
small (1-50)
Products
Photochemical inactivated vaccine platform
A platform approach for producing inactivated vaccines using riboflavin-mediated photochemical inactivation with UVA/UVB irradiation, designed to preserve antigen presentation and be adaptable to multiple pathogens.
Photo-inactivation apparatus for vaccine production
Equipment and apparatus used to apply riboflavin and controlled UVA/UVB irradiation to biological material as part of the inactivation and vaccine production process.
Photochemical inactivated vaccine platform
A platform approach for producing inactivated vaccines using riboflavin-mediated photochemical inactivation with UVA/UVB irradiation, designed to preserve antigen presentation and be adaptable to multiple pathogens.
Photo-inactivation apparatus for vaccine production
Equipment and apparatus used to apply riboflavin and controlled UVA/UVB irradiation to biological material as part of the inactivation and vaccine production process.
Services
Research and development of vaccines using photochemical inactivation methods that preserve antigen structure.
Design and execution of animal challenge studies, virology and histopathology assessments, and program activities to support advancement toward clinical testing.
Development of scalable manufacturing processes and apparatus for photochemical inactivation suited to decentralized and local production.
Management and execution of research programs funded by government agencies, including grant administration and consortium participation.
Research and development of vaccines using photochemical inactivation methods that preserve antigen structure.
Design and execution of animal challenge studies, virology and histopathology assessments, and program activities to support advancement toward clinical testing.
Development of scalable manufacturing processes and apparatus for photochemical inactivation suited to decentralized and local production.
Management and execution of research programs funded by government agencies, including grant administration and consortium participation.
Expertise Areas
- Vaccine platform development using photochemical inactivation
- Preclinical vaccine evaluation and animal challenge studies
- Whole-virion vaccine formulation
- Decentralized and low-cost vaccine manufacturing strategies
Key Technologies
- Riboflavin (vitamin B2)-mediated photochemical inactivation
- UVA/UVB irradiation for nucleic acid modification
- Whole-virion vaccine approaches
- Animal challenge models
News & Updates
The Defense Health Agency has selected Solaris Vaccines to create a safe and effective vaccine for preventing death and disease caused by the Dengue Virus.
Solaris Vaccines has been selected as a member of the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP), an assembly of industry leaders across the biopharmaceutical manufacturing spectrum.
Solaris Vaccines Awarded Funding from NIH to Develop Novel Influenza Vaccine using SolaVAX™ Platform
Solaris Vaccines received a Small Business Innovative Research (SBIR) grant from the NIH to create an improved influenza vaccine.
Dr. Izabela Ragan has joined Solaris Vaccines as Director of R&D, bringing expertise in novel vaccine technologies.
The CEO discusses the company's journey and focus on life science innovation.
VIC Technology Venture Development announced the formation of Solaris Vaccines to advance a new vaccine development platform for pandemics.
The Defense Health Agency has selected Solaris Vaccines to create a safe and effective vaccine for preventing death and disease caused by the Dengue Virus.
Solaris Vaccines has been selected as a member of the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP), an assembly of industry leaders across the biopharmaceutical manufacturing spectrum.
Solaris Vaccines Awarded Funding from NIH to Develop Novel Influenza Vaccine using SolaVAX™ Platform
Solaris Vaccines received a Small Business Innovative Research (SBIR) grant from the NIH to create an improved influenza vaccine.
Dr. Izabela Ragan has joined Solaris Vaccines as Director of R&D, bringing expertise in novel vaccine technologies.
The CEO discusses the company's journey and focus on life science innovation.
VIC Technology Venture Development announced the formation of Solaris Vaccines to advance a new vaccine development platform for pandemics.